Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Amended) A method of preparing a cancer vaccine, comprising:

(a) contacting a neoplastic cell population with a first ~~marker~~ dye,

(b) contacting an antigen presenting cell population with a second ~~marker~~ dye, wherein said first dye is different from said second dye,

(c) contacting said neoplastic cell population and said antigen presenting cell ~~populations~~ population with one another under conditions that promote cell fusion,

(d) purifying the resultant hybrid cell population by fluorescence activated cell sorting, and

(e) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle;

wherein said cell sorting does not involve antibiotic or metabolic selection and the diversity of the starting cell populations is preserved in the resultant hybrid cell population.

33. (Canceled)

34. (Canceled)

35. (Amended) The method of claim 32~~, 33 or 34,~~ wherein the resultant cell population contains less than 10% of its total population as reactant cells.

36. (Amended) The method of claim 32~~, 33 or 34,~~ wherein the resultant cell population contains less than 5% of its total population as reactant cells.

37. (Canceled)

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Amended) The method of claim 32~~, 33 or 34,~~ wherein said pharmaceutically acceptable vehicle is normal saline.

42. (Canceled)

43. (Canceled)

44. (Previously Presented) A method of preparing a tumor vaccine, comprising:

(a) contacting a tumor cell population with a first dye,

(b) contacting a dendritic cell population with a second dye,

(c) contacting said tumor cell population and said dendritic cell population with one another under conditions that promote cell fusion,

(d) purifying the resultant hybrid cell population by cell sorting, and

(e) resuspending the resultant hybrid cell population in a pharmaceutically acceptable buffer;

wherein said cell sorting does not involve antibiotic or metabolic selection, the resultant cell population contains less than 5% reactant cells, and diversity of the starting cell populations is preserved in the resultant hybrid cell population.